Tumor targeting and microenvironment-responsive nanoparticles for gene delivery

Biomaterials

Volumn 34, Issue 21, 2013, Pages 5294-5302

  Huang, Shixian ^a   Shao, Kun ^a   Kuang, Yuyang ^a   Liu, Yang ^a   Li, Jianfeng ^a   An, Sai ^a   Guo, Yubo ^a   Ma, Haojun ^a   He, Xi ^a   Jiang, Chen ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Activatable; Cell penetrating peptide; Gene delivery; Tumor microenvironment; Tumor targeting nanoparticles

Indexed keywords

ACTIVATABLE; CELL-PENETRATING PEPTIDE; GENE DELIVERY; TUMOR MICROENVIRONMENT; TUMOR TARGETING;

CELLS; CYTOLOGY; ENZYME ACTIVITY; GENE TRANSFER; LOADING; MOLECULAR BIOLOGY; NANOPARTICLES; PEPTIDES;

TUMORS;

CELL PENETRATING PEPTIDE; GELATINASE A; NANOCARRIER; PLASMID DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL MEMBRANE PERMEABILITY; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; ELECTROPHORETIC MOBILITY; GENE DELIVERY SYSTEM; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO GENE TRANSFER; INTERNALIZATION; MALE; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SYNTHESIS; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; DNA; DRUG CARRIERS; ELECTROPHORESIS; ENDOCYTOSIS; FLUORESCENCE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASMS; POLYETHYLENE GLYCOLS; POLYLYSINE; TISSUE DISTRIBUTION; TUMOR MICROENVIRONMENT;

EID: 84877040295     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.03.043     Document Type: Article

References (41)

1. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011, 63(3):131-135.
2. Liu S., Guo Y., Huang R., Li J., Huang S., Kuang Y., et al. Gene and doxorubicin co-delivery system for targeting therapy of glioma. Biomaterials 2012, 33(19):4907-4916.
3. Han L., Li J., Huang S., Huang R., Liu S., Hu X., et al. Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent. Biomaterials 2011, 32(11):2989-2998.
4. Yokoyama M. Drug targeting with nano-sized carrier systems. JArtif Organs 2005, 8(2):77-84.
5. Huang S., Li J., Han L., Liu S., Ma H., Huang R., et al. Dual targeting effect of angiopep-2-modified, DNA-loaded nanoparticles for glioma. Biomaterials 2011, 32(28):6832-6838.
6. Huang R., Ke W., Han L., Li J., Liu S., Jiang C. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. Biomaterials 2011, 32(9):2399-2406.
7. Zhang Y., Pardridge W.M. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. JPharmacol Exp Ther 2005, 313(3):1075-1081.
8. Hong M., Zhu S., Jiang Y., Tang G., Sun C., Fang C., et al. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles. JControl Release 2010, 141(1):22-29.
9. Gu F., Zhang L., Teply B.A., Mann N., Wang A., Radovic-Moreno A.F., et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci 2008, 105(7):2586-2591.
10. Montcourrier P., Silver I., Farnoud R., Bird I., Rochefort H. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis 1997, 15(4):382-392.
11. Zhang X.M., Lin Y.X., Gillies R.J. Tumor pH and its measurement. JNucl Med 2010, 51(8):1167-1170.
12. Lee E.S., Gao Z., Bae Y.H. Recent progress in tumor pH targeting nanotechnology. JControl Release 2008, 132(3):164-170.
13. Zhang W., Song J., Zhang B., Liu L., Wang K., Wang R. Design of acid-activated cell penetrating peptide for delivery of active molecules into cancer cells. Bioconjug Chem 2011, 22(7):1410-1415.
14. An M., Wijesinghe D., Andreev O.A., Reshetnyak Y.K., Engelman D.M. pH-(low)-insertion-peptide (pHLIP) translocation of membrane impermeable phalloidin toxin inhibits cancer cell proliferation. Proc Natl Acad Sci 2010, 107(47):20246-20250.
15. Na K., Lee E.S., Bae Y.H. Self-organized nanogels responding to tumor extracellular pH: pH-dependent drug release and invitro cytotoxicity against MCF-7 cells. Bioconjug Chem 2007, 18(5):1568-1574.
16. Makovitzki A., Fink A., Shai Y. Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. Cancer Res 2009, 69(8):3458-3463.
17. Matsumura S., Aoki I., Saga T., Shiba K. Atumor-environment-responsive nanocarrier that evolves its surface properties upon sensing matrix metalloproteinase-2 and initiates agglomeration to enhance T(2) relaxivity for magnetic resonance imaging. Mol Pharm 2011, 8(5):1970-1974.
18. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2(3):161-174.
19. Chabottaux V., Noel A. Breast cancer progression: insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007, 24(8):647-656.
20. Turpeenniemi-Hujanen T. Gelatinases (MMP-2 and -9) and their natural inhibitors as prognostic indicators in solid cancers. Biochimie 2005, 87(3-4):287-297.
21. Jiang T., Zhang Z., Zhang Y., Lv H., Zhou J., Li C., et al. Dual-functional liposomes based on pH-responsive cell-penetrating peptide and hyaluronic acid for tumor-targeted anticancer drug delivery. Biomaterials 2012, 33(36):9246-9258.
22. Cheng C.J., Saltzman W.M. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials 2011, 32:6194-6203.
23. Lee J.Y., Bae K.H., Kim J.S., Nam Y.S., Park T.G. Intracellular delivery of paclitaxel using oil-free, shell cross-linked HSA-multi-armed PEG nanocapsules. Biomaterials 2011, 32:8635-8644.
24. Liu J., Zhao Y., Guo Q., Wang Z., Wang H., Yang Y., et al. TAT-modified nanosilver for combating multidrug-resistant cancer. Biomaterials 2012, 33:6155-6161.
25. Patel L.N., Zaro J.L., Shen W.C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res 2007, 24(11):1977-1992.
26. Torchilin V.P. TAT peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 2008, 60(4-5):548-558.
27. Vives E., Schmidt J., Pelegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta-Rev Cancer 2008, 1786(2):126-138.
28. Vives E. Present and future of cell-penetrating peptide mediated delivery systems: "is the Trojan horse too wild to go only to Troy?". JControl Release 2005, 109(1-3):77-85.
29. Aguilera T.A., Olson E.S., Timmers M.M., Jiang T., Tsien R.Y. Systemic invivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) 2009, 1(5-6):371-381.
30. Heitz F., Morris M.C., Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009, 157(2):195-206.
31. Mai J.C., Mi Z.B., Kim S.H., Ng B., Robbins P.D. Aproapoptotic peptide for the treatment of solid tumors. Cancer Res 2001, 61(21):7709-7712.
32. Snyder E.L., Meade B.R., Dowdy S.F. Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor function. JControl Release 2003, 91(1-2):45-51.
33. Fei L., Ren L., Zaro J.L., Shen W.C. The influence of net charge and charge distribution on cellular uptake and cytosolic localization of arginine-rich peptides. JDrug Target 2011, 19(8):675-680.
34. Cottet H., Martin M., Papillaud A., Souaid E., Collet H., Commeyras A. Determination of dendrigraft poly-L-lysine diffusion coefficients by taylor dispersion analysis. Biomacromolecules 2007, 8(10):3235-3243.
35. Huang R., Liu S., Shao K., Han L., Ke W., Liu Y., et al. Evaluation and mechanism studies of PEGylated dendrigraft poly-L-lysines as novel gene delivery vectors. Nanotechnology 2010, 21(26):265101.
36. Jiang T., Olson E.S., Nguyen Q.T., Roy M., Jennings P.A., Tsien R.Y. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci 2004, 101(51):17867-17872.
37. Wender P.A., Mitchell D.J., Pattabiraman K., Pelkey E.T., Steinman L., Rothbard J.B. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci 2000, 97(24):13003-13008.
38. Sethuraman V.A., Bae Y.H. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. JControl Release 2007, 118(2):216-224.
39. La Rocca G., Pucci-Minafra I., Marrazzo A., Taormina P., Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 2004, 90(7):1414-1421.
40. Potocky T.B., Menon A.K., Gellman S.H. Cytoplasmic and nuclear delivery of a TAT-derived peptide and a beta-peptide after endocytic uptake into HeLa cells. JBiol Chem 2003, 278(50):50188-50194.
41. Pouton C.W., Seymour L.W. Key issues in non-viral gene delivery. Adv Drug Deliv Rev 2001, 46(1-3):187-203.